 Heather Moore
Concepts (140)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 11 | 2025 | 2127 | 1.250 |
Why?
| | Oxazepines | 2 | 2019 | 5 | 0.820 |
Why?
| | Imidazoles | 2 | 2019 | 234 | 0.740 |
Why?
| | Polycomb Repressive Complex 2 | 2 | 2014 | 63 | 0.490 |
Why?
| | Estrogen Receptor alpha | 2 | 2025 | 130 | 0.400 |
Why?
| | Receptors, Estrogen | 6 | 2024 | 421 | 0.390 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2013 | 275 | 0.380 |
Why?
| | Antineoplastic Agents | 2 | 2019 | 2045 | 0.310 |
Why?
| | Receptor, ErbB-2 | 4 | 2024 | 325 | 0.310 |
Why?
| | Biomarkers | 2 | 2019 | 3963 | 0.310 |
Why?
| | Carbolines | 2 | 2024 | 30 | 0.270 |
Why?
| | Patient Discharge | 3 | 2022 | 835 | 0.230 |
Why?
| | Glucuronosyltransferase | 1 | 2024 | 13 | 0.220 |
Why?
| | Cell Line, Tumor | 4 | 2025 | 3186 | 0.210 |
Why?
| | Pyridines | 2 | 2024 | 478 | 0.200 |
Why?
| | Respiration, Artificial | 2 | 2017 | 613 | 0.190 |
Why?
| | Piperazines | 1 | 2024 | 340 | 0.180 |
Why?
| | Mutation | 3 | 2025 | 3705 | 0.150 |
Why?
| | Paclitaxel | 1 | 2019 | 217 | 0.150 |
Why?
| | Continuity of Patient Care | 2 | 2017 | 272 | 0.140 |
Why?
| | Chemokines, CXC | 1 | 2017 | 70 | 0.130 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 2 | 2014 | 41 | 0.130 |
Why?
| | Female | 16 | 2025 | 68494 | 0.130 |
Why?
| | Simulation Training | 1 | 2017 | 81 | 0.130 |
Why?
| | Airway Management | 1 | 2016 | 44 | 0.130 |
Why?
| | Ventilator Weaning | 1 | 2016 | 36 | 0.120 |
Why?
| | Hedgehog Proteins | 1 | 2017 | 187 | 0.120 |
Why?
| | Surgery, Computer-Assisted | 1 | 2016 | 76 | 0.120 |
Why?
| | Laryngoscopy | 1 | 2016 | 97 | 0.120 |
Why?
| | Tracheostomy | 1 | 2016 | 121 | 0.110 |
Why?
| | Preoperative Care | 1 | 2016 | 338 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1554 | 0.110 |
Why?
| | Receptor, Notch1 | 1 | 2014 | 61 | 0.110 |
Why?
| | Lung Neoplasms | 2 | 2019 | 2340 | 0.110 |
Why?
| | Aromatase Inhibitors | 2 | 2024 | 51 | 0.100 |
Why?
| | Humans | 18 | 2025 | 129144 | 0.100 |
Why?
| | Ultrasonography | 1 | 2016 | 712 | 0.100 |
Why?
| | Mice, SCID | 1 | 2013 | 350 | 0.100 |
Why?
| | Quality Improvement | 2 | 2017 | 1095 | 0.100 |
Why?
| | Signal Transduction | 3 | 2017 | 4919 | 0.100 |
Why?
| | Gene Knockdown Techniques | 1 | 2013 | 316 | 0.100 |
Why?
| | Carcinoma | 1 | 2014 | 214 | 0.100 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2013 | 201 | 0.090 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2014 | 193 | 0.090 |
Why?
| | Postmenopause | 2 | 2023 | 349 | 0.090 |
Why?
| | Patient Care Team | 1 | 2016 | 600 | 0.090 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 1049 | 0.090 |
Why?
| | Length of Stay | 1 | 2016 | 1120 | 0.090 |
Why?
| | Caregivers | 1 | 2017 | 802 | 0.080 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2017 | 634 | 0.080 |
Why?
| | Asthma | 1 | 2022 | 2219 | 0.080 |
Why?
| | Phosphorylation | 1 | 2013 | 1710 | 0.070 |
Why?
| | Cell Movement | 1 | 2013 | 944 | 0.070 |
Why?
| | Mice | 4 | 2025 | 16905 | 0.070 |
Why?
| | Animals | 6 | 2025 | 35286 | 0.060 |
Why?
| | Estrogen Receptor Antagonists | 1 | 2023 | 2 | 0.050 |
Why?
| | Middle Aged | 5 | 2024 | 31050 | 0.050 |
Why?
| | Ki-67 Antigen | 1 | 2023 | 108 | 0.050 |
Why?
| | Cell Lineage | 1 | 2025 | 331 | 0.050 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2024 | 154 | 0.050 |
Why?
| | Estrogen Antagonists | 1 | 2022 | 45 | 0.050 |
Why?
| | Gene Frequency | 1 | 2024 | 501 | 0.050 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2024 | 204 | 0.050 |
Why?
| | Aged | 4 | 2024 | 21997 | 0.050 |
Why?
| | Haplotypes | 1 | 2024 | 475 | 0.050 |
Why?
| | Positron-Emission Tomography | 1 | 2023 | 279 | 0.050 |
Why?
| | Tamoxifen | 1 | 2022 | 195 | 0.050 |
Why?
| | Human Genome Project | 1 | 2001 | 15 | 0.050 |
Why?
| | Progesterone | 1 | 2022 | 245 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2023 | 379 | 0.040 |
Why?
| | Polymorphism, Genetic | 1 | 2024 | 637 | 0.040 |
Why?
| | Ligands | 1 | 2022 | 620 | 0.040 |
Why?
| | Receptors, Progesterone | 1 | 2022 | 341 | 0.040 |
Why?
| | Aftercare | 1 | 2022 | 203 | 0.040 |
Why?
| | Estrogens | 1 | 2022 | 346 | 0.040 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 81 | 0.040 |
Why?
| | Maximum Tolerated Dose | 1 | 2019 | 193 | 0.040 |
Why?
| | Genotype | 1 | 2024 | 1833 | 0.040 |
Why?
| | Adult | 4 | 2024 | 35469 | 0.040 |
Why?
| | Genome, Human | 1 | 2001 | 392 | 0.040 |
Why?
| | Sequence Analysis, DNA | 1 | 2001 | 776 | 0.040 |
Why?
| | Cell Proliferation | 1 | 2025 | 2368 | 0.030 |
Why?
| | Transitional Care | 1 | 2017 | 36 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2022 | 737 | 0.030 |
Why?
| | Long-Term Care | 1 | 2017 | 92 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2019 | 607 | 0.030 |
Why?
| | Anilides | 1 | 2017 | 70 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1268 | 0.030 |
Why?
| | Up-Regulation | 1 | 2017 | 838 | 0.030 |
Why?
| | Microarray Analysis | 1 | 2014 | 116 | 0.030 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2014 | 132 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2019 | 10192 | 0.030 |
Why?
| | Male | 5 | 2024 | 63456 | 0.030 |
Why?
| | Infant | 2 | 2017 | 8975 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2014 | 328 | 0.030 |
Why?
| | Child, Preschool | 2 | 2017 | 10456 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 712 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2016 | 1429 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1833 | 0.020 |
Why?
| | Blotting, Western | 1 | 2014 | 1202 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2022 | 1896 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2014 | 1155 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2014 | 1678 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2014 | 1205 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 4075 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 4882 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2016 | 3077 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3231 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2019 | 7037 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2017 | 2536 | 0.020 |
Why?
| | Child | 2 | 2017 | 20768 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2017 | 5438 | 0.020 |
Why?
| | Lung | 1 | 2017 | 3927 | 0.010 |
Why?
| | Neoplasms | 1 | 2017 | 2442 | 0.010 |
Why?
| | Chromosome Banding | 1 | 2001 | 21 | 0.010 |
Why?
| | Pseudogenes | 1 | 2001 | 18 | 0.010 |
Why?
| | Physical Chromosome Mapping | 1 | 2001 | 17 | 0.010 |
Why?
| | Chromosomes, Artificial, Bacterial | 1 | 2001 | 17 | 0.010 |
Why?
| | Consensus Sequence | 1 | 2001 | 73 | 0.010 |
Why?
| | DNA, Intergenic | 1 | 2001 | 24 | 0.010 |
Why?
| | Gene Duplication | 1 | 2001 | 67 | 0.010 |
Why?
| | Retroelements | 1 | 2001 | 44 | 0.010 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2001 | 111 | 0.010 |
Why?
| | Genes | 1 | 2001 | 227 | 0.010 |
Why?
| | CpG Islands | 1 | 2001 | 152 | 0.010 |
Why?
| | United States | 1 | 2017 | 13825 | 0.010 |
Why?
| | Introns | 1 | 2001 | 251 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 2001 | 504 | 0.010 |
Why?
| | Exons | 1 | 2001 | 341 | 0.010 |
Why?
| | Young Adult | 1 | 2016 | 12385 | 0.010 |
Why?
| | Species Specificity | 1 | 2001 | 574 | 0.010 |
Why?
| | Adolescent | 1 | 2016 | 20297 | 0.010 |
Why?
| | Evolution, Molecular | 1 | 2001 | 464 | 0.010 |
Why?
| | Computational Biology | 1 | 2001 | 596 | 0.010 |
Why?
| | Genetic Variation | 1 | 2001 | 937 | 0.010 |
Why?
| | Databases, Factual | 1 | 2001 | 1266 | 0.010 |
Why?
| | Proteins | 1 | 2001 | 941 | 0.010 |
Why?
| | Algorithms | 1 | 2001 | 1613 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2001 | 2059 | 0.010 |
Why?
| | Phenotype | 1 | 2001 | 3071 | 0.010 |
Why?
|
|
Moore's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|